Last reviewed · How we verify
NCT03623568
Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Phase 4 trial testing glecaprevir/pibrentasvir tablets in Kidney Failure. Withdrawn.
31 December 2020
Quick facts
| Lead sponsor | Raymond T. Chung, MD |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Start date | 15 February 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 15 April 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- glecaprevir/pibrentasvir tablets — full drug profile →
Conditions studied
- Kidney Failure — all drugs for Kidney Failure →
- Kidney Diseases — all drugs for Kidney Diseases →
- Hepatitis C — all drugs for Hepatitis C →
Sponsor
Raymond T. Chung, MD — full company profile →
Who can join
Adults 30 to 70, any sex, with Kidney Failure or Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a proof of concept, single center study for the donation of HCV-positive kidney to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03623568
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Failure
Currently open trials in the same condition.
- NCT07492511 — Renal and Hepatic Abnormal Doppler Patterns in Trauma · recruiting
- NCT06243731 — A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation · recruiting
- NCT06642597 — STarting incrEmental Prescription of Peritoneal Dialysis · NA · recruiting
- NCT06343727 — A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) · NA · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
Other Raymond T. Chung, MD trials
Trials by the same sponsor.
- NCT03026023 — Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03623568 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Raymond T. Chung, MD
- Last refreshed: 3 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03623568.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing